Fresenius Kabi is allowed to begin marketing Otulfiits fourth biosimilar approved in the U.S.no later than Feb
It was really frustrating doing everything right since I can remember: watching my calorie intake, being active, exercising, and no matter what I did, nothing worked, she said
The proportions of patients who discontinued study drug in the 56-week trials were 27% for the SAXENDA-treated group and 35% for the placebo-treated group, and in the 160-week trial the proportions of patients who discontinued were 47% and 55%, respectively
Pediatr Res 54:688695 Wainwright MS, Kohli R, Whitington PF, Chace DH (2006) Carnitine treatment inhibits increases in cerebral carnitine esters and glutamate detected by mass spectrometry after hypoxia-ischemia in newborn rats
ELISA detection of MPO-DNA complexes in human plasma is error-prone and yields limited information on neutrophil extracellular traps formed in vivo